Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8694600 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SLC15A1KMT2AMAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8649093 | 0.98 | ALDH1A1 (0.51) | ALDH1A1SLC15A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL7421478 | 0.87 | SLC15A1 (0.56) | ALDH1A1SLC15A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL2135198 | 0.86 | ALDH1A1 (0.60) | ALDH1A1SLC15A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL313062 | 0.86 | ALDH1A1 (0.60) | ALDH1A1SLC15A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL728752 | 0.86 | ALDH1A1 (0.60) | ALDH1A1SLC15A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL10870099 | 0.86 | ALDH1A1 (0.49) | ALDH1A1SLC15A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL27677759 | 0.85 | ALDH1A1 (0.50) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL7460011 | 0.84 | ANPEP (0.48) | ALDH1A1SLC15A1SLC1A1 | |
| SCHEMBL6864986 | 0.84 | ANPEP (0.48) | ALDH1A1SLC15A1SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646015-B1 | ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | FERRING INT CENTER SA (CH) | 2020-04-22 | — | — | EP | disclosed |
| EP-1534334-B1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | BELROSE PHARMA INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130267562-A1 | ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | NEXMED HOLDINGS, INC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2646015-A2 | ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | NexMed Holdings, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| CN-103073618-A | Preparation method for benzyloxycarbonyl alanyl alanine | GL BIOCHEM SHANGHAI LTD | 2013-05-01 | — | — | CN | disclosed |
| WO-2012075107-A2 | ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | NEXMED HOLDINGS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-2338513-A2 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON, INC. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7897647-B2 | Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro | ENZON PHARMACEUTICALS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1534334-A4 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20060286065-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | BELROSE PHARMA INC. | 2006-12-21 | — | — | US | disclosed |
| US-5461176-A | Reacting alanine methyl ester with oxalyl chloride, treating with ammonia in methanol, reducing amides with diborane in tetrahydrofuran, neutralizing with sodium ethoxide to yield free amine | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| US-5371086-A | Circulatory disorders side effect reduction | THE GREEN CROSS CORPORATION (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5329048-A | Reaction of tert-butyloxycarbonylaniline with 1,1' carbonyl diimidazole then ethylenediamine, then acidification to remove tert-butyloxycarbonyl | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0577753-A1 | BIS-NAPHTHALIMIDES CONTAINING AMINO-ACID DERIVED LINKERS AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-01-12 | — | — | EP | disclosed |
| US-5262415-A | FOR TREATING DISEASES OF THE CIRCULATORY SYSTEM | THE GREEN CROSS CORPORATION (JP) | 1993-11-16 | — | — | US | disclosed |
| US-5206249-A | Diastereoisomers; enantiomorphs; antitumor agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| WO-1992017453-A1 | BIS-NAPHTHALIMIDES CONTAINING AMINO-ACID DERIVED LINKERS AS ANTICANCER AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0506008-A1 | Bis-naphthalimides containing amino-acid derived linkers as anticancer agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| EP-0503627-A1 | Aminopyridine compounds | THE GREEN CROSS CORPORATION (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-4554100-A | ENZYME INHIBITORS | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267562-A1 | ACTIVE ENANTIOMER OF DODECYL 2-(N,N-DIMETHYLAMINO)-PROPIONATE | DBI, SLC34A2, PDAP1 | ALDH1A1 1823/4885SLC15A1 148/4885KMT2A 4494/4885 |
| US-20060286065-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | CD44, PAICS, PCBP1 | ALDH1A1 646/4885SLC15A1 1439/4885KMT2A 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.